Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 1.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,506 shares of the company’s stock after acquiring an additional 1,054 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in BioNTech were worth $8,658,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Eagle Bay Advisors LLC bought a new stake in BioNTech during the second quarter worth approximately $33,000. Resurgent Financial Advisors LLC purchased a new position in shares of BioNTech during the fourth quarter valued at approximately $47,000. Signaturefd LLC boosted its position in shares of BioNTech by 18,750.0% during the first quarter. Signaturefd LLC now owns 377 shares of the company’s stock valued at $47,000 after buying an additional 375 shares during the period. EverSource Wealth Advisors LLC purchased a new position in shares of BioNTech during the fourth quarter valued at approximately $58,000. Finally, Heritage Wealth Management LLC boosted its position in shares of BioNTech by 100.8% during the fourth quarter. Heritage Wealth Management LLC now owns 474 shares of the company’s stock valued at $71,000 after buying an additional 238 shares during the period. 16.73% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
BNTX has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft dropped their target price on BioNTech from $135.00 to $120.00 in a research report on Thursday, May 18th. Morgan Stanley restated an “equal weight” rating and set a $119.00 target price on shares of BioNTech in a research report on Monday, July 31st. HC Wainwright dropped their target price on BioNTech from $198.00 to $181.00 in a research report on Thursday, June 1st. HSBC began coverage on BioNTech in a report on Friday, July 14th. They issued a “buy” rating and a $124.00 price target for the company. Finally, Redburn Partners upgraded BioNTech from a “neutral” rating to a “buy” rating and boosted their price target for the company from $165.00 to $170.00 in a report on Wednesday, May 17th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $160.29.
BioNTech Stock Down 7.5 %
BioNTech stock opened at $98.50 on Tuesday. The business has a fifty day moving average of $107.87 and a two-hundred day moving average of $119.67. The company has a quick ratio of 12.68, a current ratio of 12.95 and a debt-to-equity ratio of 0.01. The firm has a market cap of $23.74 billion, a P/E ratio of 3.79 and a beta of 0.18. BioNTech SE has a twelve month low of $95.50 and a twelve month high of $188.99.
BioNTech (NASDAQ:BNTX – Get Free Report) last posted its earnings results on Monday, May 8th. The company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $1.87. The company had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.09 billion. BioNTech had a return on equity of 32.52% and a net margin of 51.03%. BioNTech’s revenue was down 80.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $15.98 earnings per share. On average, analysts forecast that BioNTech SE will post 5.68 earnings per share for the current fiscal year.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Read More
- Five stocks we like better than BioNTech
- EV Stocks and How to Profit from Them
- 8 Best Meme Stocks to Buy Now
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Is Now The Time To Buy XLF Financial ETF?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Three Ways To Play The Rise In Oil Prices
Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTX – Free Report).
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
